W.L. Gore & Associates said yesterday that it launched its Gore Tag conformable thoracic stent graft with active control in Australia, touting that the first procedures with the device have been performed in the region.
The first implant procedures with the device were performed by Dr. Ian Spark of Adelaide, Australia’s Flinders Medical Centre, Gore said.
“The Gore Tag conformable stent graft is a reliable and trusted device that I have used for TEVAR procedures with my patients for many years. The availability of the new Gore Active Control System is an exciting advancement because it significantly enhances the control I have when deploying the stent graft, making it easier to accommodate challenging anatomies. The angulation and precision deployment capabilities could decrease the risk of common complications and reduce the likelihood for future interventions that result in additional trauma for patients and costs to providers. Both the control in the delivery system and long-term benefits of the stent graft mark significant advancement for the medical community,” Dr. Spark said in a press release.
The Gore Tag conformable thoracic stent graft is designed for thoracic endovascular aortic repair procedures, and features a new delivery system intended for controlled, staged deployment, the Flagstaff, Ariz.-based company said.
The device’s active control system is intended to improve conformability, Gore said, to allow for optimal wall apposition to improve performance in complex anatomies.
“Since Gore pioneered the first TEVAR device in Europe two decades ago, we have welcomed feedback from our physician partners to innovate and evolve our stent graft offerings for better long-term patient care. The Gore Tag Device family has a legacy of trusted performance and durability, and we knew we could build on that by enhancing control during deployment which would help make TEVAR procedures more predictable for physicians. Physicians can now deploy our thoracic stent graft in the descending thoracic aorta with more operative ease, even in those patients with extremely angulated aortic arches, and meet the clinical and practical challenges of TEVAR with confidence. With this latest product iteration, Gore is continuing its unparalleled commitment to developing solutions that advance endovascular solutions for diseases of the aorta,” Gore vascular biz lead Eric Zacharias said in a prepared statement.
In April, Gore said it won expanded FDA indications for its Cardioform septal occluder, now cleared for the closure of patent foramen ovale to reduce the risk of recurrent ischemic stroke in certain patients.